Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Blast Overpressure Longitudinal Study (BLES)

maanantai 18. toukokuuta 2026 päivittänyt: Uniformed Services University of the Health Sciences

Blast Overpressure Longitudinal Exposure Study (BLES)

The goal of this observational study is to learn about the impact of low-level blast exposure in U.S. Special Operations Forces personnel. The main questions it aims to answer are:

What advanced brain imaging changes are related to clinical presentation after low-level blast exposure? What are the relationships between low-level blast exposure and common groups of symptoms after concussion?

Participants will:

  • Undergo advanced brain imaging
  • Answer questionnaires
  • Complete clinical tests
  • Provide blood, urine, and saliva samples
  • Wear blast sensors

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Yksityiskohtainen kuvaus

Participants in this observational study are active-duty U.S. Special Operations Forces personnel between the ages of 18 and 50. This study is designed to characterize the neurological and clinical effects associated with repeated low-level blast exposure (LLBE) in this population. Concerns have emerged that cumulative exposure to sub-concussive blast overpressure (BOP), even in the absence of a diagnosable concussion, may be associated with subtle changes in brain structure and function over time. Due to the nature of their operational and training environments, Special Operations Forces personnel may experience repeated LLBE and are therefore an important population for longitudinal investigation.

Participation involves in-person assessments and data collection conducted over a period of approximately 4-5 years. The schedule of study activities includes baseline, daily, weekly, monthly, quarterly, and annual assessments. Baseline and annual study visits include advanced magnetic resonance imaging (MRI) and require travel to Walter Reed National Military Medical Center. Specifically, this study includes the use of the Microstructure Anatomy Gradient for Neuroimaging with Ultrafast Scanning (MAGNUS) 3.0 Tesla MRI.

Throughout the study period, participants complete standardized questionnaires and clinical assessments and provide biological samples, including blood, urine, and saliva, at specified intervals. Participants also contribute measures on a daily, weekly, monthly, quarterly, and annual basis. They will wear blast sensors throughout their participation in the study.

The total planned enrollment for the study is approximately 250 participants across multiple sites, with an estimated 60 participants enrolled at Fort Bragg, NC. Enrollment and follow-up are expected to occur over a 4-5 year period.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

250

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

  • Yhdysvallat
    • Maryland
      • Bethesda, Maryland, Yhdysvallat, 20889
        • Walter Reed National Military Medical Center
        • Ottaa yhteyttä:
    • North Carolina
      • Fort Bragg, North Carolina, Yhdysvallat, 28310
    • Texas
      • San Antonio, Texas, Yhdysvallat, 78236
        • Wilford Hall Ambulatory Surgical Center
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

The target population is 250 SOF personnel, particularly those who are regularly exposed to occupational low-level blast exposure. Approximately 10% of the sample will be recruited as a control group of low/no exposure personnel.

Kuvaus

Inclusion Criteria:

  • Active duty
  • U.S. SOF personnel
  • 18-50 years old

Exclusion Criteria:

  • Subjects will be excluded only if their participation will significantly interfere with validity of data collection or safety during the study (e.g., they have conditions that might result in harm or injury during research procedures).
  • Example: pregnancy (balance considerations)
  • Example: being unable to undergo MRI testing (i.e., they have non-MRI compatible devices, imbedded metal fragments such as shrapnel, and/or severe claustrophobia; these MRI contraindications will be screened using an MRI Safety Questionnaire)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
High exposure (experimental)
Special Operations Forces personnel with higher occupational blast overpressure exposure as measured by blast sensor(s)
Low/No exposure (control)
Special Operations Forces personnel with lower occupational blast overpressure exposure as measured by blast sensor(s)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Effective axonal radii mapping
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The primary outcome measure in this study will be effective axonal radii (r_eff) mapping derived from ultra-high performance diffusion magnetic resonance imaging using the MAGNUS system and its correlations to low-level blast exposure.
At baseline and annually through study completion, an average of 5 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Ohio State University TBI Identification Method
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Ohio State University TBI Identification Method is a standardized approach for collecting an individual's comprehensive history of traumatic brain injuries through a structured interview lasting 3-5 minutes.
At baseline and annually through study completion, an average of 5 years
Concussion Clinical Profiles Screening
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Concussion Clinical Profiles Screening (CP Screen) tool will be used to measure the five concussion clinical subtypes (profiles) and two modifiers. The CP Screen is a 29-item post-concussion symptom inventory. Subjects rate the severity of 29 symptoms on a scale from 0 (None [Not experiencing this symptom.]) to 3 (Severe). The CP Screen total score is a sum of the 29 items (range 0 to 87, higher scores mean a worse outcome). Subscale scores range from 0 to 15 for vestibular, ocular-motor, anxiety/mood, and post-traumatic headache (migraine); 0 to 9 for cognitive; 0 to 12 for sleep; and 0 to 6 for cervical spine.
At baseline and annually through study completion, an average of 5 years
Neurobehavioral Symptom Inventory
Aikaikkuna: At baseline and weekly through study completion, an average of 5 years
The Neurobehavioral Symptom Inventory (NSI) is a 22-item post-concussion symptom inventory. The NSI total score is a sum of the 22 items (range 0 to 88, higher scores mean a worse outcome).
At baseline and weekly through study completion, an average of 5 years
Headache Impact Test
Aikaikkuna: At baseline and weekly through study completion, an average of 5 years
The Headache Impact Test (HIT-6) is a 6-item assessment of the negative impact of headaches. The HIT-6 total score is a sum of the 6 items (range 36 to 78, higher scores mean a worse outcome).
At baseline and weekly through study completion, an average of 5 years
modified Military Concussion Readiness Inventory for Dizziness and Balance
Aikaikkuna: At baseline and quarterly through study completion, an average of 5 years
The modified Military Concussion Readiness Inventory for Dizziness and Balance (MCRI-DB) is a military-specific measure of the handicapping effects dizziness and imbalance (similar to the Dizziness Handicap Inventory). The modified MCRI-DB total score is a sum of the 25 items (range 0 to 100, higher scores mean a worse outcome).
At baseline and quarterly through study completion, an average of 5 years
Composite Autonomic Symptom Score (COMPASS) 31
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Composite Autonomic Symptom Score (COMPASS) 31 is a 31-item self-reported evaluation that measures autonomic symptoms across six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal (combining constipation, diarrhea, and gastroparesis domains), bladder, and pupillomotor. The COMPASS-31 total score is a sum of the 31 items (range 0 to 100, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Pittsburgh Sleep Quality Index
Aikaikkuna: PSQI at baseline and annually through study completion, an average of 5 years
The Pittsburgh Sleep Quality Index (PSQI) is a 18-item self-reported evaluation of sleep quality to distinguish between "good" and "poor" sleepers, and identify significant sleep disturbances of various types. There are an additional five items for evaluating sleep quality, as reported by a bed partner/roommate. The PSQI total score is a sum of the 18 items (range 0 to 21, higher scores mean a worse outcome).
PSQI at baseline and annually through study completion, an average of 5 years
Brief Pittsburgh Sleep Quality Index
Aikaikkuna: B-PSQI monthly through study completion (except at baseline and annually when the 18-item PSQI [see above] will be used), an average of 5 years
The Brief Pittsburgh Sleep Quality Index (B-PSQI) is a 6-item self-reported evaluation of sleep quality to distinguish between "good" and "poor" sleepers, and identify significant sleep disturbances of various types. The B-PSQI total score is a sum of the 6 items (range 0 to 21, higher scores mean a worse outcome).
B-PSQI monthly through study completion (except at baseline and annually when the 18-item PSQI [see above] will be used), an average of 5 years
STOP-Bang
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The STOP-Bang questionnaire will be used as a screening instrument for obstructive sleep apnea. It uses a yes/no checklist for snoring, tiredness, observed apnea, high blood pressure, BMI, age, neck circumference, and gender (male sex). Scores on the STOP-Bang range from 0 to 8 (higher scores mean a worse outcome) with ≥3 indicating a positive screening.
At baseline and annually through study completion, an average of 5 years
Neck Disability Index
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Neck Disability Index (NDI) is a 10-item self-reported evaluation that measures how neck pain impacts daily life and the level of self-perceived disability in individuals with neck pain. The NDI total score is a sum of the 10 items (range 0 to 50, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
PTSD Checklist for DSM-5 (PCL-5)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report instrument designed to evaluate the 20 symptoms of PTSD as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The PCL-5 total score is a sum of the 20 items (range 0 to 80, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
General Anxiety Disorder (GAD-7)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The General Anxiety Disorder (GAD-7) is a 7-item assessment for identifying likely cases of generalized anxiety disorder. The GAD-7 total score is a sum of the 7 items (range 0 to 21, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Patient Health Questionnaire (PHQ-9)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Patient Health Questionnaire (PHQ-9) is a 9-item assessment for evaluating the presence and severity of depressive symptoms. The PHQ-9 total score is a sum of the 9 items (range 0 to 27, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Quality of Life after Brain Injury (QOLIBRI)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Quality of Life after Brain Injury (QOLIBRI) evaluates health-related quality of life in individuals following TBI, incorporating the individual's perspective on their health, functioning, and well-being. The QOLIBRI consists of 37 items divided into four scales: Cognition, Self, Daily Life and Autonomy, and Social Relationships. The QOLIBRI total score is a sum of the 37 items (range 0 to 100, higher scores mean a better outcome).
At baseline and annually through study completion, an average of 5 years
Caffeine Consumption Questionnaire - Revised
Aikaikkuna: At baseline and weekly through study completion, an average of 5 years
The Caffeine Consumption Questionnaire - Revised is a six-page self-report measure to estimate caffeine consumption. This outcome measure can be scored in three ways: a conservative estimate using minimum caffeine concentration values, a mean estimate based on average concentrations, and a liberal estimate using maximum concentration values.
At baseline and weekly through study completion, an average of 5 years
Supplement Frequency Questionnaire
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Supplement Frequency Questionnaire is a one-page survey that assesses supplement use across 16 categories over the past year. The 16 categories are: multivitamins (one-a-day, B-complex, antioxidant); vitamins A, C, E, B-12, and D; beta-carotene; folic acid; calcium; selenium; iron; zinc; fish oil/omega-3 fatty acids; and garlic. This outcome measure can be scored by calculating total nutrient intake for each nutrient from supplements by multiplying frequency × duration × default dose.
At baseline and annually through study completion, an average of 5 years
Alcohol Use Disorders Identification Test - Consumption (AUDIT-C)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) is a screening tool used to identify hazardous drinking and potential alcohol use disorders. The AUDIT-C total score is a sum of the 3 items (range 0 to 12, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Penn State Cigarette Dependence Index
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Penn State Cigarette Dependence Index is a 10-item measure of nicotine dependence. The Penn State Cigarette Dependence Index total score is a sum of the 10 items (range 0 to 20, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Penn State Electronic Cigarette Dependence Index
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Penn State Electronic Cigarette Dependence Index is a 10-item measure of nicotine dependence. The Penn State Electronic Cigarette Dependence Index total score is a sum of the 10 items (range 0 to 20, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Penn State Nicotine Pouch Dependence Index
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Penn State Nicotine Pouch Dependence Index is a 10-item measure of nicotine dependence. The Penn State Nicotine Pouch Dependence Index total score is a sum of the 10 items (range 0 to 20, higher scores mean a worse outcome).
At baseline and annually through study completion, an average of 5 years
Military Acute Concussion Evaluation 2 (MACE2)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Military Acute Concussion Evaluation 2 (MACE2) is the standard of care for concussion screening and diagnosis in the military, and consists of: description of incident (potentially concussive event); alteration of consciousness or memory; symptoms; history of concussion, headache disorder or migraine, depression, anxiety, or other behavioral health concerns; cognitive exam; neurological exam; and Vestibular/Ocular Motor Screening (VOMS; see below). The MACE2's multiple measurements will be aggregated to arrive at one reported value - positive or negative.
At baseline and annually through study completion, an average of 5 years
Military Acute Concussion Evaluation 2 (MACE2) with embedded Vestibular/Ocular Motor Screening (VOMS)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Vestibular/Ocular Motor Screening (VOMS) is a brief clinical screening tool (<5 minutes) for vestibular and ocular motor symptoms and impairment after concussion and consists of seven items: smooth pursuits, horizontal saccades, vertical saccades, near-point convergence (NPC), horizontal vestibulo-ocular reflex (VOR), vertical VOR, and visual motion sensitivity. The VOMS' multiple measurements will be aggregated to arrive at one reported value - positive or negative.
At baseline and annually through study completion, an average of 5 years
Sway mobile device application
Aikaikkuna: At baseline and weekly through study completion, an average of 5 years
The Sway mobile device application (Sway Medical, Inc., Tulsa, OK) will be used to assess symptoms, cognition, and balance. Sway's multiple measurements will be aggregated to arrive at one reported value - positive or negative.
At baseline and weekly through study completion, an average of 5 years
COncussion BALance Test (COBALT)
Aikaikkuna: At baseline and quarterly through study completion, an average of 5 years
Subjects will undergo COncussion BALance Test (COBALT) (Bertec Corporation, Columbus, OH) testing. Each of the eight conditions in the manufacturer's research-only protocol will be performed for two 20-sec trials during which errors will be recorded by the clinician and sway velocity will be recorded by the force plate. The COBALT's multiple measurements will be aggregated to arrive at two reported values - sway velocity and number of errors.
At baseline and quarterly through study completion, an average of 5 years
King-Devick Test
Aikaikkuna: At baseline and weekly through study completion, an average of 5 years
The King-Devick Test (King-Devick technologies, inc., Oak Brook, IL) is a short, timed assessment in which subjects rapidly read aloud single-digit numbers.
At baseline and weekly through study completion, an average of 5 years
EYE-SYNC®
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The EYE-SYNC® (NeuroSync, Inc., Holliston, MA) will be used to administer the Vestibular/Ocular Motor Screening, as well as pro-saccades and anti-saccades.
At baseline and annually through study completion, an average of 5 years
PLR®-4000
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The PLR®-4000 (NeurOptics, Inc., Irving, CA) will be used to measure pupil size and pupillary reactivity. Eight measurements from the device (maximum diameter, minimum diameter, percent change, latency of constriction, constriction velocity, maximum constriction velocity, dilation velocity, and time to reach 75% recovery) will be aggregated to arrive at one reported value - normal or abnormal (in comparison to published normative data).
At baseline and annually through study completion, an average of 5 years
Automated Neuropsychological Assessment Metrics (v4) Military Expanded
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Military Battery consists of Participant Information (military demographics), Sleepiness Scale, TBI Questionnaire, Mood Scale, Simple Reaction Time, Code Substitution - Learning, Procedural Reaction Time, Mathematical Processing, Matching to Sample, Code Substitution - Delayed, and Simple Reaction Time (Repeated) modules. The ANAM's multiple measurements will be aggregated to arrive at one reported value - normal or abnormal (in comparison to published normative data stratified by age [5-year increments], gender, race/ethnicity and education).
At baseline and annually through study completion, an average of 5 years
Wechsler Abbreviated Scale of Intelligence - Second Edition (WASI-II)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
The Wechsler Abbreviated Scale of Intelligence - Second Edition (WASI-II) is a rapid (approximately 30-minute) assessment of cognitive functioning. A composite score, the Full Scale IQ-4 Subtest (FSIQ-4), ranges from "Very Superior" (≥130) to "Extremely Low/Impaired" (<70) and higher scores mean a better outcome.
At baseline and annually through study completion, an average of 5 years
Videonystagmography (VNG) / oculomotor and vestibular function testing
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
Subjects will undergo videonystagmography (VNG) / oculomotor and vestibular function testing (smooth pursuit, horizontal and vertical saccades, caloric testing, ocular and cervical vestibular-evoked myogenic potentials [oVEMP and cVEMP]) performed by a Research Audiologist. The results of this battery of testing will be aggregated to arrive at one reported value - normal or abnormal (in comparison to published normative data).
At baseline and annually through study completion, an average of 5 years
Video Head Impulse (vHIT)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
Subjects will undergo video Head Impulse Test (vHIT) testing with the ICS® Impulse (Natus; Middleton, WI). This is a standard clinical test of the semicircular canals. Vestibulo-ocular reflex gain will be determined using the ratio of the area under the curve of eye velocity relative to the area under the curve of head velocity (after saccade traces are removed) from onset to offset of head velocity.
At baseline and annually through study completion, an average of 5 years
Wireless Automated Hearing Test System (WAHTS)
Aikaikkuna: At baseline and annually through study completion, an average of 5 years
Subjects will undergo Wireless Automated Hearing Test System (WAHTS) (WAHTS Hearing LLC; Lebanon, NH) portable, wireless audiometry testing.
At baseline and annually through study completion, an average of 5 years

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
quantitative EEG via the NeuroCatch®
Aikaikkuna: At baseline and quarterly through study completion, an average of 5 years
Cognition will be explored using quantitative EEG via the NeuroCatch® (NeuroCatch Inc., Canada) brain vital sign framework. This framework includes three event-related brain potentials (ERPs): auditory N100 (auditory sensation), auditory oddball P300 (basic attention), and auditory speech processing N400 (cognitive processing). NeuroCatch's multiple measurements will be aggregated to arrive at one reported value - normal or abnormal.
At baseline and quarterly through study completion, an average of 5 years
Blast sensor-measurement of blast exposure(s)
Aikaikkuna: Daily through study completion, an average of 5 years
Subjects will wear blast sensors continuously during training for the duration of their study participation. The blast sensors' multiple measurements will be aggregated to arrive at one reported value - total exposure (number of exposure events exceeding 4psi).
Daily through study completion, an average of 5 years
Self-report of blast exposure(s)
Aikaikkuna: Daily through study completion, an average of 5 years
Self-report of environment (i.e., indoor/outdoor, under overhang, etc.), role (shooter/breacher, observer, instructor), position (i.e., prone supported, prone unsupported, kneeling, standing, etc.), weapon (i.e., make/model, caliber, etc.), number of rounds, date/time, and duration of training will also be collected on training days. The questionnaire-based self-report of blast exposure(s) will be aggregated to arrive at one reported value - estimated total exposure (number of exposure events).
Daily through study completion, an average of 5 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Uniformed Services University of the Health Sciences

Yhteistyökumppanit

The Geneva Foundation
MIT Lincoln Laboratory

Tutkijat

  • Päätutkija: Tony T Yuan, PhD, Uniformed Services University of the Health Sciences
  • Opintojen puheenjohtaja: Vincent B Ho, MD, Uniformed Services University of the Health Sciences

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Perjantai 1. toukokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. elokuuta 2030

Opintojen valmistuminen (Arvioitu)

Torstai 1. elokuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 24. maaliskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 18. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 26. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 26. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 18. toukokuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. maaliskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 25-21750
  • HU00012520052 (Muu apuraha/rahoitusnumero: U.S. Special Operations Command)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

Research data may be shared, when permitted by USSOCOM, upon reasonable request to the Principal Investigator.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa